Pharmacodynamics of doxycycline and tetracycline against staphylococcus pseudintermedius: Proposal of canine-specific breakpoints for doxycycline

Journal of Clinical Microbiology

Volumn 51, Issue 11, 2013, Pages 3547-3554

  Maaland, Marit Gaastra ^a   Papich, Mark G ^b   Turnidge, John ^c   Guardabassi, Luca ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; TETRACYCLINE;

ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIOSTASIS; BACTERIUM ISOLATE; CONTROLLED STUDY; DISK DIFFUSION; DOG; DRUG BLOOD LEVEL; DRUG EFFICACY; IN VITRO STUDY; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STAPHYLOCOCCUS PSEUDINTERMEDIUS; WILD TYPE;

ANIMALS; ANTI-BACTERIAL AGENTS; DOG DISEASES; DOGS; DOXYCYCLINE; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; TETRACYCLINE;

EID: 84886574362     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01498-13     Document Type: Article

References (44)

1. Chopra I, Roberts M.2001.Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance.Microbiol.Mol.Biol.Rev.65:232-260.
2. Bryskier A.2005.Tetracyclines, p 642-651.In Bryskier A (ed), Antimicrobial agents.Antibacterials and antifungals.ASM Press, Washington, DC.
3. Bannoehr J, Guardabassi L.2012.Staphylococcus pseudintermedius in the dog: taxonomy, diagnostics, ecology, epidemiology and pathogenicity.Vet. Dermatol.23:253-266.
4. Sasaki T, Tsubakishita S, Tanaka Y, Sakusabe A, Ohtsuka M, Hirotaki S, Kawakami T, Fukata T, Hiramatsu K.2010.Multiplex-PCR method for species identification of coagulase-positive staphylococci.J. Clin. Microbiol.48:765- 769.
5. Bannoehr J, Franco A, Iurescia M, Battisti A, Fitzgerald JR.2009.Molecular diagnostic identification of Staphylococcus pseudintermedius.J. Clin. Microbiol.47:469-471.
6. Clinical and Laboratory Standards Institute.2008.Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard-third edition.M31-A3.Clinical and Laboratory Standards Institute, Wayne, PA.
7. Aarestrup FM, Agerso Y, Gerner-Smidt P, Madsen M, Jensen LB.2000.Comparison of antimicrobial resistance phenotypes and resistance genes in Enterococcus faecalis and Enterococcus faecium from humans in the community, broilers, and pigs in Denmark.Diagn.Microbiol.Infect.Dis.37: 127-137.
8. Akinbowale OL, Peng H, Barton MD.2007.Diversity of tetracycline resistance genes in bacteria from aquaculture sources in Australia.J.Appl. Microbiol.103:2016-2025.
9. Blondeau JM, Borsos S, Blondeau LD, Blondeau BJ.2012.In vitro killing of Escherichia coli, Staphylococcus pseudintermedius and Pseudomonas aeruginosa by enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat.Vet.Microbiol.155: 284-290.
10. Gutierrez L, Velasco ZH, Vazquez C, Vargas D, Sumano H.2012. Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs.Acta Vet.Scand.54:35.
11. van Gool FJPJE, Santoul C, Giuseppin-Huet AM.1988.Doxycycline: pharmacokinetics and suggested dosage in dogs and cats.Tijdschr.Diergeneeskd. 113:1189-1193.(in Dutch.)
12. Bidgood TL, Papich MG.2003.Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs.Am. J. Vet. Res.64:1040-1046.
13. Schach von Wittenau M, Twomey TM.1971.Disposition of doxycycline by man and dog.Chemotherapy 16:217-228.
14. Wilson BJ, Norris JM, Malik R, Martin PA, Wigney DI, Baral R, Govendir M.2006.Susceptibility of bacteria from feline and canine urinary tract infections to doxycycline and tetracycline concentrations attained in urine four hours after oral dosage.Aust.Vet.J.84:8-11.
15. Wilson RC, Kemp DT, Kitzman JV, Goetsch DD.1988.Pharmacokinetics of doxycycline in dogs.Can.J.Vet.Res.52:12-14.
16. Barza M, Brown RB, Shanks C, Gamble C, Weinstein L.1975.Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs.Antimicrob. Agents Chemother.8:713-720.
17. Riond JL, Vaden SL, Riviere JE.1990.Comparative pharmacokinetics of doxycycline in cats and dogs.J.Vet.Pharmacol.Ther.13:415-424.
18. Ambrose PG.2006.Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the Society of Infectious Diseases Pharmacists.Pharmacotherapy 26:129-134.
19. Frei CR, Wiederhold NP, Burgess DS.2008.Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokineticpharmacodynamic models with Monte Carlo simulation.J. Antimicrob. Chemother.61:621-628.
20. Roberts JA, Kirkpatrick CMJ, Lipman J.2011.Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients.J. Antimicrob. Chemother.66:227-231.
21. Andes D, Craig W.2007.Pharmacokinetics and pharmacodynamics of tetracyclines, p 267-278.In Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (ed), Antimicrobial pharmacodynamics in theory and clinical practice, 2nd ed.Informa Healthcare USA, New York, NY.
22. Christianson J, Andes D, Craig W.2001.Magnitude of the 24-h AUC/ MIC required for efficacy of doxycycline (DOXY) against Streptococcus pneumoniae (SP) in a murine thigh-infection model.Clin. Infect. Dis.33:1169.
23. Agwuh KN, MacGowan A.2006.Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines.J. Antimicrob. Chemother.58:256-265.
24. LaPlante KL, Leonard SN, Andes DR, Craig WA, Rybak MJ.2008.Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against communityassociated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models.Antimicrob. Agents Chemother.52:2156-2162.
25. Papich MG.2011.Saunders handbook of veterinary drugs, 3rd ed.Elsevier-Saunders, St.Louis, MO.
26. Papich MG, Riviere JE.2009.Tetracycline antibiotics, p 1524.In Riviere JE, Papich MG (ed), Veterinary pharmacology and therapeutics, 9th ed.Wiley-Blackwell Publishing, Ames, IA.
27. Turnidge J, Kahlmeter G, Kronvall G.2006.Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.Clin.Microbiol.Infect.12:418-425.
28. Clinical and Laboratory Standards Institute.2008.Development of in vitro susceptibility testing criteria and quality control parameters.Approved standard-third edition.M23-A3.Clinical and Laboratory Standards Institute, Wayne, PA.
29. Turnidge J, Paterson DL.2007.Setting and revising antibacterial susceptibility breakpoints.Clin.Microbiol.Rev.20:391-408.
30. Kim SE, Kim S, Jeong M, Lee Y, Ahn JT, Park YW, Ahn JS, Lee E, Ryu DY, Seo K.2013.Experimental determination of a subantimicrobial dosage of doxycycline hyclate for treatment of periodontitis in beagles.Am. J. Vet. Res.74:130-135.
31. Ganiere JP, Medaille C, Mangion C.2005.Antimicrobial drug susceptibility of Staphylococcus intermedius clinical isolates from canine pyoderma.J.Vet.Med.B Infect.Dis.Vet.Public Health 52:25-31.
32. Weese JS, Sweetman K, Edson H, Rousseau J.2013.Evaluation of minocycline susceptibility of methicillin-resistant Staphylococcus pseudintermedius.Vet. Microbiol.162:968-971.
33. Kahlmeter G, Brown DFJ, Goldstein FW, MacGowan AP, Mouton JW, Osterlund A, Rodloff A, Steinbakk M, Urbaskova P, Vatopoulos A.2003.European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria.J. Antimicrob. Chemother.52:145-148.
34. Schwarz S, Roberts MC, Werckenthin C, Pang YJ, Lange C.1998.Tetracycline resistance in Staphylococcus spp.from domestic animals.Vet.Microbiol.63:217-227.
35. Roberts MC.1996.Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution.FEMS Microbiol.Rev.19:1-24.
36. Taylor DE, Chau A.1996.Tetracycline resistance mediated by ribosomal protection.Antimicrob. Agents Chemother.40:1-5.
37. Norstrom M, Sunde M, Tharaldsen H, Mork T, Bergsjo B, Kruse H.2009.Antimicrobial resistance in Staphylococcus pseudintermedius in the Norwegian dog population.Microb.Drug Resist.15:55-59.
38. Schwarz S, Wibawan IWT, Lammler C.1994.Distribution of genes conferring combined resistance to tetracycline and minocycline among group-B streptococcal isolates from humans and various animals.Zentralbl.Bakteriol.281:526-533.
39. Jones RN, Stilwell MG, Wilson ML, Mendes RE.2013.Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Grampositive pathogens.Diagn.Microbiol.Infect.Dis.76:69-72.
40. Cunha BA, Domenico P, Cunha CB.2000.Pharmacodynamics of doxycycline.Clin.Microbiol.Infect.6:270-273.
41. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL.2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.J. Antimicrob. Chemother.55:601-607.
42. Zelenitsky SA, Ariano RE, Zhanel GG.2011.Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data.J. Antimicrob. Chemother.66:343-349.
43. Martinez MN, Papich MG, Drusano GL.2012.Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/ pharmacodynamic target.Antimicrob. Agents Chemother.56: 2795-2805.
44. Sapadin AN, Fleischmajer R.2006.Tetracyclines: nonantibiotic properties and their clinical implications.J.Am.Acad.Dermatol.54:258-265.